The primary objective of this study is to determine whether intranasal application of aminoglycoside (Neosporin) increases local nasal innate immune responses compared to placebo control in healthy participants.

开始日期2022-09-01

申办/合作机构

Yale University

[+1]

NCT00997139 / CompletedN/AIIT

Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment

Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.

开始日期2009-09-01

申办/合作机构

Northwestern University

100 项与杆菌肽/硫酸新霉素/硫酸多粘菌素B 相关的临床结果

登录后查看更多信息

100 项与杆菌肽/硫酸新霉素/硫酸多粘菌素B 相关的转化医学

登录后查看更多信息

100 项与杆菌肽/硫酸新霉素/硫酸多粘菌素B 相关的专利（医药）

登录后查看更多信息

项与杆菌肽/硫酸新霉素/硫酸多粘菌素B 相关的文献（医药）

2023-09-09·Cureus

Comparative Evaluation of the Effect of Six Different Low-Surface-Tension Vehicles on the Penetration of Modified Triple Antibiotic Paste in Dentinal Tubules: An In Vitro Study

Article

作者: Thote, Akshayprasad P ; Kibe, Aradhana N ; Nikhade, Pradnya P

Background Modified triple antibiotic paste (MTAP) helps in the elimination of microorganisms which is imperative for the success of endodontic therapy. The intracanal medicament powders must be mixed with vehicles for better handling and penetration in the root canals. The purpose of this study is to compare the effect of six low-surface-tension vehicles on the penetration of MTAP in dentinal tubules. Methodology The root apices of 60 single-rooted human mandibular premolars were resected to obtain 12mm length. After biomechanical preparation, intracanal medicaments were prepared by mixing with the six vehicles (Group 1- Bupivacaine, Group 2- Sodium ether lauryl sulfate, Group 3- Neosporin H, Group 4- Chlorhexidine gluconate, Group 5- Chitosan, and Group 6- Polyethylene glycol) with MTAP and Rhodamine B dye. Middle and apical transverse sections were scanned under a confocal laser scanning microscope. The data were statistically analyzed using the one-way ANOVA test and the level of significance was p<0.05. Results The maximum depth of penetration was seen in Group 2 (MTAP with sodium ether lauryl sulfate) followed by Group 5 (MTAP with chitosan), Group 4 (MTAP with chlorhexidine gluconate), Group 1 (MTAP with bupivacaine), and Group 6 (MTAP with polyethylene glycol), and the least penetration by Group 3 (MTAP with Neosporin H). The depth of penetration in the middle level was in the order of Group 2 followed by Group 4, Group 5, Group 3, Group 6, and Group 1. The depth of penetration in the apical level was in the order of Group 2 followed by Group 5, Group 1, Group 4, Group 6, and Group 3. The overall depth of penetration was significantly higher at the middle level than at the apical level. Conclusion Group sodium ether lauryl sulfate showed the maximum depth of penetration in both the middle and apical areas. The least depth of penetration in the middle area was seen in group bupivacaine and the apical area by group Neosporin H.

2022-07-18·Cureus

Autosensitization Triggered by Neosporin Use: A Unique Phenomenon

作者: Sragi, Zara ; Bathla, Jasdeep S ; Sugg, Kyle ; Tur, Komalpreet

Interface dermatitis is a type of dermatological insult to the dermo-epidermal skin junction. When this reaction causes secondary dermatosis that occurs distally on the body, it is known as autosensitization or autoeczematization. Here, we present the case of a middle-aged gentleman, with a medical history including human immunodeficiency virus, non-adherent to highly active antiretroviral therapy, initially presenting due to chronic recurring cellulitis on the left lower leg that had become progressively erythematous and tender to palpation. A few days later, he developed an intensely pruritic, papular rash on his face and chest. Following further investigation, he reported using Neosporin ointment on the leg rash prior to admission which had then caused allergic contact dermatitis. Ultimately, the patient was diagnosed with acute interface dermatitis due to Neosporin use, which led to a secondary autosensitization reaction involving his head, neck, and arms. This case illustrates the importance of thorough history taking and clinical suspicion to appropriately diagnose this phenomenon, further demonstrating the temporal association between allergic contact dermatitis and autosensitization.

2020-06-01·Clinics and research in hepatology and gastroenterology

Biliary antibiotics irrigation for E. coli-induced chronic proliferative cholangitis and hepatolithiasis: A pathophysiological study in rabbits

Article

作者: Cheng, Nan-Sheng ; Ma, Wen-Jie ; Wang, Jun-Ke ; Shi, Yu-Jun ; Hu, Hai-Jie ; Yang, Qin ; Li, Fu-Yu ; Wu, Zhen-Ru

BACKGROUND:

The gram-negative bacteria secreted endotoxin, Lipopolysaccharide (LPS), plays important roles in the formation and recurrence of hepatolithiasis and chronic biliary inflammation in patients of Southeast Asia. We aimed to elucidate the anti-inflammatory effect and mechanism of local antibiotics irrigation on chronic proliferative cholangitis (CPC) and hepatolithiasis.

METHODS:

Escherichia coli was injected into rabbit bile ducts to induce CPC. Rabbits were divided into sham operation (SO), povidone-iodine, Metronidazole plus chlorhexidine, ofloxacin, furacillin, Neosporin® G.U., and CPC groups. Local irrigation was performed for 28 days after CPC was established. Residual E. coli and LPS, and the expression of MCP-1, CD14, COX-2, VEGF, IL-6, NF-κB, TNF-α, Fas, TGF-β1, α-SMA, Collagen-I, β-glucuronidase, PKC, C-myc, and Mucin 5AC were assessed in bile duct tissues.

RESULTS:

The residual E. coli and LPS, and expression of MCP-1, CD14, COX-2, IL-6, NF-κB, TNF-α, Fas, TGF-β1, α-SMA, β-glucuronidase, PKC, C-myc, and Mucin 5AC in the SO, povidone-iodine, Metronidazole plus chlorhexidine, ofloxacin, and Neosporin® G.U. groups were significantly lower than those in the furacillin and CPC groups (P<0.05). VEGF and Collagen-I levels in the SO, povidone-iodine, metronidazole plus chlorhexidine, and ofloxacin groups were significantly lower than those in the furacillin, Neosporin® G.U., and CPC groups (P<0.05).

CONCLUSIONS:

LPS affects the pathophysiology of E. coli caused chronic proliferative cholangitis and hepatolithiasis recurrence. Local antibiotics irrigation could prevent chronic proliferative cholangitis and stones formation by decreasing LPS-induced proinflammatory and profibrotic cytokines release. Povidone iodine, metronidazole plus chlorhexidine, and ofloxacin were more effective than Neosporin® G.U. and furacillin.

项与杆菌肽/硫酸新霉素/硫酸多粘菌素B 相关的新闻（医药）

2024-05-10

·生物谷

奇迹抗生素？！PNAS | 新研究揭示常用抗生素新霉素鼻喷预防COVID-19与流感的潜力

人类呼吸道病毒感染往往会引起广泛的疾病，每年在全球范围内会造成大量的发病和死亡。近日，一篇发表在国际杂志Proceedings of the National Academy of Sciences上题为“Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract”的研究报告中，来自耶鲁大学医学院等机构的科学家们通过研究发现，常见的非处方抗生素新霉素，可能成为抵御包括COVID-19和流感在内的多种呼吸道病毒感染的秘密武器。文章中，研究人员通过鼻腔给予动物模型新霉素（一种常见的抗生素）治疗，测试了其预防或治疗呼吸道病毒感染的有效性，随后他们发现，相同的鼻腔治疗方法（使用的是非处方药膏Neosporin）成功激活了健康人体内的干扰素刺激基因（ISGs，interferon-stimulated genes），迅速建立起一道强大的抗病毒防线。研究者Iwasaki说道，这是一项令人兴奋的研究发现，即一种廉价的非处方抗生素药膏能刺激机体激活一种抗病毒反应。这项研究支持了新霉素在抵御动物模型机体病毒性疾病中的关键预防和治疗性作用，并展示出了其能有效阻断病毒的感染和传播。呼吸道病毒每年会在全球影响数百万人的健康，截至2024年2月，因冠状病毒SARS-CoV-2所引起的COVID-19已经在全球引起了7.745亿例病例，导致690万人发生死亡；流感病毒每年在全球也会造成高达500万例严重病例，且会导致50万名患者发生死亡。常用抗生素新霉素或有望帮助抵御人类呼吸道病毒感染图片来源：Proceedings of the National Academy of Sciences (2024). DOI:10.1073/pnas.2319566121目前，大多数用于抵御呼吸道病毒感染的疗法（包括抗病毒药物、单克隆抗体和恢复期血浆疗法）都能通过静脉注射或口服，其重点能阻断当前感染的进展。研究人员表示，以鼻腔为中心的疗法或许有更好地机会在感染扩散到下呼吸道并引起严重疾病之前阻断感染。Dela Cruz博士说道，这项多学科合作的研究个工作结合了动物肺部感染建模实验和人类研究评估的重要见解，而且这种鼻腔内疗法在人体试验中同样引发了强烈的ISGs表达，预示着其作为预防措施的巨大潜力。本文研究结果表明，研究人员或许有望优化这种廉价的常用抗生素，从而有效预防病毒性疾病发生以及其在人群中的扩散，尤其是在资源非常有限的全球社区中，由于这种方法具有一定的宿主导向特性，因此，这种方法无论针对何种病毒或许都是有效的。综上，本文研究结果表明，新霉素或能被潜在用来作为一种宿主定向型抗病毒策略，从而预防和治疗人类呼吸道病毒感染。参考文献：Tianyang Mao, Jooyoung Kim, Mario A. Peña-Hernández, et al. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract, Proceedings of the National Academy of Sciences (2024). DOI: 10.1073/pnas.2319566121本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

临床研究

2024-02-29

·Endpoints

Novo Holdings invests in macrocycle startup Orbis as once-overlooked molecules get new interest

At long last, macrocycles are spinning into the spotlight. On Thursday, Orbis Medicines launched with €26 million in seed funding from European VC fund Forbion and Novo Holdings, the investment arm of Novo Nordisk’s parent foundation. The startup is focused on developing peptide drugs based on macrocycles, which are small chemical rings. Most macrocycle drugs, such as cyclosporine or a component of Neosporin, have been discovered in nature, but the molecules were for a long time left on the sidelines by drug developers because they had difficulty passing through membranes, an important quality for many pill-based medicines. However, recent advances in designing peptides have shown it’s possible to overcome that obstacle and have rekindled interest in the potential for macrocyclic medicines.

2023-07-25

·PRNewswire

Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer, addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion. The DxI 9000 Analyzer has shown capability to develop increasingly sensitive and clinically relevant assays enabling the platform to keep pace with tomorrow's testing requirements as healthcare providers and pharmaceutical companies take aim at evermore challenging diseases. Continue Reading We believe that there is more clinical data available from a patient's blood sample than is currently accessible. Tweet this The DxI 9000 Analyzer innovations address today’s speed, reliability, reproducibility, quality, and menu expansion demands. At the same time, the novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays, ensuring the system is able to meet the healthcare needs of tomorrow. According to Zivjena Vucetic, M.D., Ph.D., Chief Medical Officer and Senior Vice President, Medical & Scientific Affairs, President, Beckman Coulter Diagnostics, "We believe that there is more clinical data available from a patient's blood sample than is currently accessible. Early system evaluations and conversations with users suggest that the DxI 9000 Analyzer opens up new opportunities to quantify trace amounts of key biomarkers in blood samples. The implications extend throughout healthcare systems. For example, in Alzheimer's disease, adding a highly accurate and more patient-friendly testing option to current diagnostic solutions, with the goal of providing alternative options to PET-imaging or a lumbar puncture, amplifies the impact of new pharmaceutical therapies and ultimately improves patient outcomes." Ray Divilley, Chief Medical Officer, Mayo University Hospital, Ireland, was an early evaluator of the DxI 9000 Analyzer added, "With the DxI 9000, Beckman Coulter has successfully produced a platform that addresses today's laboratories needs for speed, accuracy, and reliability. Based on our use and evaluation of the system in our lab, we were able to get actionable results back quicker to doctors and ultimately patients as they consider treatment options." Recently, Beckman Coulter Diagnostics and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases. Initial assay development efforts will focus on the recently introduced DxI 9000 Access Immunoassay Analyzer and the widespread installed base of Access Family Immunoassay Analyzers. "This collaboration with Beckman Coulter will help accelerate the deployment of our portfolio of new, novel neurodegenerative biomarkers to laboratories and clinicians around the world. As the pre-eminent provider of leading-edge immunoassays to the diagnostics industry, this partnership is an important step to speed the transition of these markers from research to clinical use in all major geographies and to bring a higher standard of care to patients and their families in the battle against this debilitating disease," stated Goki Ishikawa, President & CEO, Fujirebio Holdings, Inc. In addition to advancing diagnostics capabilities, the DxI 9000 excels in improving clinical laboratory operations. ZeroDaily Maintenance highlights the embedded innovations that drive the DxI 9000 Analyzer's uptime performance. Beta users attest to ZeroDaily Maintenance redefining their workday with no daily maintenance requirements, thereby reducing annual maintenance routines by up to 96%. Building on Beckman Coulter's workflow and automation leadership, PrecisionVision Technology is unmatched in its ability to inspect, identify and prevent erroneous reporting in real time. PrecisionVision automated safeguards include tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check reduces the risk of reporting flawed data and increases system reliability and reproducibility. The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide. Additional Resources Link to DxI 9000 Access Immunoassay Analyzer media kit Follow and connect with Beckman Coulter Diagnostics via LinkedIn, Twitter, and Facebook. About Beckman Coulter. Inc. A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Beckman Coulter is part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies. Headquartered in Brea, Calif., it has more than 11,000 global team members. ©2023 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2023-11982 SOURCE Beckman Coulter, Inc.

诊断试剂

100 项与杆菌肽/硫酸新霉素/硫酸多粘菌素B 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
睑缘炎	美国	Casper Pharma LLC	1971-05-10
结膜炎	美国	Casper Pharma LLC	1971-05-10
角膜炎	美国	Casper Pharma LLC	1971-05-10
角结膜炎	美国	Casper Pharma LLC	1971-05-10
未特指的睑结膜炎	美国	Casper Pharma LLC	1971-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2019	N/A	伤口感染	310	Topical Bacitracin Zinc+Neomycin Sulfate+Polymyxin B (Neosporin)	淵遞選鑰窪範醖範築窪(醖襯願遞膚廠衊構醖廠) = 艱淵簾壓觸選艱觸膚築獵積憲鏇築製鹽網鹹醖 (膚獵壓憲蓋觸鏇積鹹衊 )	-	2019-07-01
				Gentamicin	淵遞選鑰窪範醖範築窪(醖襯願遞膚廠衊構醖廠) = 獵鏇鑰艱製獵艱憲鏇築獵積憲鏇築製鹽網鹹醖 (膚獵壓憲蓋觸鏇積鹹衊 )